Lymphoma

A Phase 3, Randomized, Double-blind Study of PF-05280586 versus Rituximab for the first-line treatment of Patients with CD20-Positive, Low Tumor Burden, Follicular Lymphoma.

The purpose of this study is to compare the efficacy of rituximab-Pfizer to rituximab- EU when administered as a first-line treatment to patients with CD20-positive, low tumor burden follicular lymphoma.

Further purposes of this study include:

  • Finding out the safety and tolerability of rituximab-Pfizer and rituximab-EU
  • Determine overall response rate

Who can join?

Eligible participants may include those with:

  • Untreated CD20- positive follicular lymphoma
  • No symptoms of lymphoma

What is Involved?

  • Study commitment for all visits
  • Routine blood testing as well as study specific testing
  • Physical examinations
  • Evaluation of your progress using CT, MRI or PET scans

A Phase 3, Randomized, Double-Blind Study of Duvelisib administered in combination with Rituximab and Bendamustine vs Placebo administered in combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma

Purpose

The primary purpose of the study is to test if adding Duvelisib to Bendamustine and Rituximab is effective in stopping the growth of cancer cells in the body. This study will also:

  • Collect information to assess your general health, well-being and overall quality of life (QOL) through completion of a questionnaire that asks you questions about how you are feeling.

Who can join?

Eligible participants may include those with:

  • Follicular, Marginal Zone or Small Lymphocytic Lymphoma
  • Previously treated with standard treatment
  • Require treatment now

What is involved?

  • Study commitment for all visits
  • Routine blood testing as well as study specific testing
  • Physical examinations
  • Evaluation of your progress using CT, MRI or PET scans